Beta 3-adrenoceptors in the cardiovascular system

The sympathetic system is central in the understanding of numerous physiological and physiopathological phenomena. During the last decade, the characterization of a new beta-adrenoceptor subtype, beta(3), in addition to beta(1) and beta(2)-adrenoceptor in the cardiovascular system has changed the vi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical hemorheology and microcirculation 2007, Vol.37 (1-2), p.193-204
Main Authors: Gauthier, Chantal, Sèze-Goismier, Camille, Rozec, Bertrand
Format: Article
Language:English
Subjects:
Adrenergic beta-Agonists - pharmacology
Adrenergic beta-Agonists - therapeutic use
Cardiovascular System - physiopathology
Heart Failure - drug therapy
Heart Failure - etiology
Humans
Hypertension - drug therapy
Hypertension - etiology
Receptors, Adrenergic, beta-3 - physiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The sympathetic system is central in the understanding of numerous physiological and physiopathological phenomena. During the last decade, the characterization of a new beta-adrenoceptor subtype, beta(3), in addition to beta(1) and beta(2)-adrenoceptor in the cardiovascular system has changed the view of the roles of the sympathetic system. In heart, beta(3)-adrenoceptor stimulation produce an opposite effect to that induced by beta(1) and beta(2)-adrenoceptors suggesting that in normal heart, the negative inotropic effect induced by the beta(3)-adrenergic stimulation might play a role of a "safety-valve" during intense adrenergic stimulation. In vessels, all beta-adrenoceptors subtypes, beta(1), beta(2) and beta(3), mediate a vasodilation. As beta(3)-adrenoceptors are activated at higher concentrations of catecholamines than beta(1) and beta(2)-adrenoceptors, they could play the roll of a receptor reserve. beta(3)-adrenoceptors are overexpressed in heart failure and hypertension and could constitute a new therapeutic target. In addition, the efficiency of some beta-blockers such as nebivolol could result from an action on beta(3)-adrenoceptors.
ISSN:1386-0291